Endovascular Treatment for Stroke in the Back of the Brain, Starting After 24 Hours
Tests clearing blocked brain arteries in adults whose stroke began over 24 hours earlier.
Plain-language title generated from the registry record
Registry title: Endovascular Treatment for Posterior Circulation Ischemic Stroke Post 1 Day （24 Hours）
Key facts
- Where
- Wuhan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a stroke in the back part of the brain who come to hospital more than 24 hours after it began. It tests a procedure that removes the clot.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Stroke in the back of the brain caused by a blocked basilar artery or both vertebral arteries (V4). It began more than 24 hours but within 14 days ago. NIHSS score of 4 or higher. The brain scan score pc-ASPECTS must be 6 or more.
- Earlier treatment
- No clot removal with a device must have been tried before joining. The blood vessel must not have already reopened.
- Biomarker or test result
- A scan (CTA/MRA/DSA) must confirm the blocked vessel. Before the stroke, the mRS score (a daily-function score) must have been 0 or 1.
Main reasons for not taking part
- Bleeding in the brain on CT or MRI
- Severe disability before the stroke (mRS 2 or higher)
- Pregnancy
- Platelet count below 50,000/uL
- Blood pressure above 220 mmHg (top number) or 120 mmHg (bottom number)
Read by machine on 9 November 2026.
Where in China
- Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Trial code
- NCT07699029
- Record updated
- 30 July 2026
- Original description
To evaluate the efficacy and safety of endovascular therapy for posterior circulation ischemic stroke presenting more than 24 hours after symptom onset.Read full original descriptionShow less
Endovascular Treatment for Posterior Circulation Ischemic Stroke Post 1 Day （24 Hours） A Randomized Controlled Clinical Trial On Efficacy
To evaluate the efficacy and safety of endovascular therapy for posterior circulation ischemic stroke presenting more than 24 hours after symptom onset.
Inclusion: Age ≥ 18 years old; Baseline NIHSS score of 4 or higher, maintained prior to randomization; Stroke onset or more than 24 hours since the last known good state, but within 14 days; CTA/MRA/DSA confirmed occlusion of the responsible vessel in basilar artery or intracranial segments of both vertebral arteries (V4); Modified Rankin Scale (mRS) score of 0 or 1 pre-stroke; The subject or their legally authorized representative has signed the informed consent form for the study.
Exclusion: Evidence of vascular recanalization prior to randomization; Attempted use of a neurothrombectomy device to remove the clot prior to randomization; Currently participating in a study involving other investigational drugs or devices; Hemorrhage on CT or MRI; Based on the judgment of the treating physician, the patient is considered unlikely to benefit from the trial (e.g., advanced dementia, severe pre-stroke disability (mRS ≥ 2), or high risk of early mortality); Major comorbidities that may interfere with outcome assessment and follow-up (e.g., severe heart failure, renal failure, etc.); Uncontrolled seizures at the time of stroke onset, if they interfere with obtaining an accurate baseline NIHSS; Posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) < 6 on non-contrast CT or CT angiography source images or MR with diffusion-weighted imaging; Severe, persistent hypertension (systolic blood pressure > 220 mmHg or diastolic blood pressure > 120 mmHg); Known allergies to iodine, heparin, anesthetics, or other explicit contraindications to the endovascular treatment procedure; Other serious, progressive, or end-stage diseases (as determined by the investigator) or a life expectancy of less than 6 months; Any other conditions that the investigator believes may interfere with the endovascular procedure or pose significant risk to the subject during the procedure; Baseline platelet count <50,000/uL; Known hereditary or acquired bleeding disorders, coagulation factor deficiencies, or recent oral anticoagulant therapy with an International Normalized Ratio (INR) > 3; Complete cerebellar infarct with significant mass effect and compression of the fourth ventricle,or bilateral thalamic infarction on CT or MRI; Suspected purulent embolism, with a suspicion of bacterial endocarditis; Pregnancy; Evidence of intracranial tumor on CT or MRI (excluding meningioma); CTA/MRA showing excessive tortuosity of the cervical vessels, which may interfere with endovascular treatment; Suspicion of aortic dissection based on medical history and CTA/MRA findings.